<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00904046</url>
  </required_header>
  <id_info>
    <org_study_id>Study00000125</org_study_id>
    <secondary_id>1R01DK081423</secondary_id>
    <nct_id>NCT00904046</nct_id>
  </id_info>
  <brief_title>Pathophysiology of Uric Acid Nephrolithiasis</brief_title>
  <acronym>IUAN</acronym>
  <official_title>Pathophysiology of Uric Acid Nephrolithiasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Takeda Pharmaceuticals North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has two aims:&#xD;
&#xD;
      Aim 1: To determine the presence of accumulation of fat within cells and the functional&#xD;
      consequences of this in the kidney by correlating kidney fat content with urine test results.&#xD;
&#xD;
      Aim 2: The investigators will evaluate the effect of thiazolidinedione (pioglitazone) on&#xD;
      excess fatty acid accumulation in kidney tissue and its correlation with uric acid stone&#xD;
      formation in subjects with uric acid stones.&#xD;
&#xD;
      Pioglitazone is already U.S. Food &amp; Drug Administration (FDA)-approved for the treatment of&#xD;
      type 2 diabetes, but is not approved by the FDA for treating or preventing or diagnosing&#xD;
      stone risk.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will use a combination of cell culture, animal, and human studies employing some of&#xD;
      the latest technologies in magnetic resonance spectroscopy and single-photon emission&#xD;
      computed tomography, combined with classical physiology, biochemistry, and molecular biology&#xD;
      to test four interrelated hypotheses. There is increased uptake of free fatty acids into the&#xD;
      kidney as a result of higher circulating levels as well as preferential transport by the&#xD;
      proximal tubule as part of a &quot;conditioning&quot; effect. The increased provision of free fatty&#xD;
      acid supplies metabolic substrate for ATP generation hence reducing the consumption of other&#xD;
      substrates such as glutamine, which is the principal source of ammoniagenesis by the proximal&#xD;
      tubule. This substrate competition, or metabolic switch, can lower the formation of the major&#xD;
      urinary buffer ammonia, even in the absence of injury to the proximal tubule. With sustained&#xD;
      lipid loading of the proximal tubule that exceeds its oxidative capacity, lipid storage is&#xD;
      first activated but with time, toxic lipid metabolites may build up. We have evidence that&#xD;
      excess saturated fat, which is prevalent in the Western diet, leads to proximal tubule&#xD;
      lipotoxicity manifested as endoplasmic reticulum (ER) leakage/stress, and we propose that&#xD;
      defective ammoniagenesis is part of a broader lipotoxic phenotype. We further propose that&#xD;
      accumulation of a specific lipid species may be responsible for the toxicity. To test whether&#xD;
      proximal tubule steatosis and lipotoxicity in humans have a functional consequence, we will&#xD;
      study uric acid stone formers. Having previously shown that thiazolidinediones (TZD) reduce&#xD;
      renal steatosis and lipotoxicity and improve ammonium excretion in animals, we have initiated&#xD;
      a randomized intervention trial with TZD or placebo in human uric acid stone formers. The&#xD;
      interim analysis showed that after 6 months of TZD therapy, stone formers had improved&#xD;
      urinary biochemical parameters and reduced propensity for uric acid precipitation. We will&#xD;
      continue this trial but add a novel highly sensitive method to non-invasively measure renal&#xD;
      fat, testing whether improvement in urinary biochemistry associates with reduction of renal&#xD;
      fat. This proposal addresses fundamental concepts of renal tubular lipid biology and&#xD;
      lipotoxicity, and clinically will shift the paradigm of uric acid stone therapy from empiric&#xD;
      urinary alkalinization to specific reduction in renal fat. We will also introduce&#xD;
      cutting-edge human imaging studies for kidney research.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 5, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reversal of renal lipotoxicity will occur with pioglitazone.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Uric Acid Kidney Stone Disease</condition>
  <arm_group>
    <arm_group_label>Pioglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For 60 Aim 2 Subjects Only - Pioglitazone (Actos)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>For 60 Subjects in Aim 2 Only - Placebo for Pioglitazone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>30 mg orally daily for 6 months</description>
    <arm_group_label>Pioglitazone</arm_group_label>
    <other_name>Thiazolidinedione</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo taken orally once a day for 6 months.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects with uric acid kidney stone disease&#xD;
&#xD;
          -  Age &gt; 21 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body weight&gt; 350 lb&#xD;
&#xD;
          -  Chronic alcohol use&#xD;
&#xD;
          -  Chronic liver disease&#xD;
&#xD;
          -  Chronic renal disease&#xD;
&#xD;
          -  Anemia&#xD;
&#xD;
          -  Contraindication to pioglitazone use:&#xD;
&#xD;
               -  history of congestive heart failure NYHA class III or IV&#xD;
&#xD;
               -  significant pedal edema&#xD;
&#xD;
               -  liver failure&#xD;
&#xD;
               -  not willing to practice an effective contraception for the duration of the study&#xD;
&#xD;
          -  Thiazolidinedione use in the preceding 18 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Khashayar Sakhaee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ann Heard-Sakhaee, RN</last_name>
    <phone>214-648-4893</phone>
    <email>Ann.Heard-Sakhaee@UTSouthwestern.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marsha Roberts, RN</last_name>
    <phone>214-648-0399</phone>
    <email>marsha.roberts@UTSouthwestern.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UT Southwestern Medical Center - Center for Mineral Metabolism</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-8885</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.utsouthwestern.edu/education/medical-school/departments/min-metab-center/research.html</url>
    <description>Center for Mineral Metabolism Website</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 15, 2009</study_first_submitted>
  <study_first_submitted_qc>May 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2009</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Khashayar Sakhaee</investigator_full_name>
    <investigator_title>Professor of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Uric acid</keyword>
  <keyword>Nephrolithiasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>2,4-thiazolidinedione</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

